Summary of T-PTLD cases at our institution
| Patient | Time to T-PTLD (mo) | Clinical presentation | Histology | Treatment | Outcome |
|---|---|---|---|---|---|
| 1 | 9 | Fever; prolonged EB viremia; involvement of spleen, retroperitoneal lymph nodes, and liver | Monomorphic T cell lymphoma (EBV+) | Reduction of immunosuppression Mammalian target of rapamycin inhibitor Rituximab Chemotherapy (CEOP) |
Death 4 mo after diagnosis |
| 2 | 119 | Fever; splenomegaly; lymph node involvement of neck, axilla, mediastinum, mesentery, retroperitoneum, and inguinal area | Angioimmunoblastic T cell lymphoma (EBV+) | Reduction of immunosuppression Mammalian target of rapamycin inhibitor Chemotherapy (CEOP) |
Complete response |
| 3 | 104 | Presacral mass (6.2 × 1.7 cm), radiating pain, cauda equina syndrome | Monomorphic peripheral T cell lymphoma (EBV–) | - | Death 1 mo after diagnosis |
| 4 | 136 | Mass-like consolidation and patchy GGO in the left lower lobe of the lung | Extranodal NK/T cell lymphoma (EBV+) | Chemotherapy (IMEP/Oncaspar, CEOP) | Stable disease |
| 5 | 352 | Skin nodule | Primary cutaneous gamma-delta T cell lymphoma (EBV–) | Chemotherapy (CEOP, gemcitabine) Radiotherapy |
Death 17 mo after diagnosis |
T-PTLD, T cell posttransplantation lymphoproliferative disorder; EB, Epstein-Barr; EBV, EB virus; CEOP, cyclophosphamide, epirubicin, vincristine, and prednisolone; GGO, ground-glass opacity; NK, natural killer; IMEP, ifosfamide, mesna, methotrexate, etoposide, and prednisolone.